AVACEN & Fibromyalgia Treatment Market Expansion

avacen & fibromyalgia

The Fibromyalgia Treatment Market is Expected to Grow at a CAGR of 17.5% During the Forecast Period of 2017 To 2023.

In a study conducted by Market Research Future, the fibromyalgia treatment market is expected to grow at a CAGR of 17.5% during the forecast period of 2017 To 2023. In 2017, Frost & Sullivan recognized AVACEN Medical with the 2017 European New Product Innovation Award for its AVACEN 100. In part, Frost & Sullivan’s recognition was based on a peer-reviewed clinical efficacy study published in 2017. This study reported that out of 22 fibromyalgia patients evaluated, those who received the AVACEN 100 device treatment for 15 minutes twice a day demonstrated an overall reduction of more than 40% in their widespread pain index scores after 28 days. Out of these subjects, 93% reported a reduction of 29.4% or more in widespread pain index scores. Also, 62% reported a lower tender point count of two or more points while 57% reported a reduction of 20% or more in overall symptom severity score rating.

Fibromyalgia is a condition that causes lasting and debilitating muscle pain and fatigue. Symptoms include musculoskeletal pain alongside memory and sleep disorders, depression, and headaches. These may be accompanied by anxiety and irritable bowel syndrome. This disease is said to tamper with the brain’s pain sensations. A fibromyalgia patient normally experiences migraine, headaches, and TMJ (temporomandibular joint) disorders.

It is noted that the rising occurrences of traumatic stress and road accidents is the key factor driving the fibromyalgia treatment market. According to a study published in the Pain Research and Management Journal, in 2014, it was found that physical trauma is followed by the fibromyalgia syndrome. In the study, conducted with a specific cohort of individuals involved in motor vehicle collisions, it was found that 8% of individuals developed widespread chronic pain. Fibromyalgia is characterized by widespread chronic pain. The study has also demonstrated the incidence rate of fibromyalgia in the survivors of a train crash in Israel which was 15%.

Other factors, such as increasing cases of rheumatic diseases, growing awareness among the population, rising geriatric population, unmet medical needs in the fibromyalgia treatment, and the rising popularity of Chinese treatment options are also promoting the growth of the market. Fibromyalgia is considered as a confounding factor for the diagnosis and the assessment of the rheumatic disease activity.

With the growing awareness of fibromyalgia and market growth coupled with demand for non-invasive therapies to reduce pain, device-based treatment such as that provided by the AVACEN medical device can be a solution for many. The AVACEN 100 is FDA-cleared for marketing in the United States for the temporary relief of joint pain associated with arthritis; and muscular relaxation.

This article relies on Fibromyalgia Treatments Market Research Report- Global Forecast To 2023 from Market Research Future